Innate immunity represents the host's first line of defense and relies on immediate recognition of pathogens. A major component of innate immunity is the complement system. Its activation has multiple effects including activation of mast cells, enhanced clearance of bacteria and targeting of antigen to the lymphoid compartment. An important step in complement activation is covalent attachment of activated C3 to pathogen surface as this provides a ligand for complement receptors CD21 and CD35 which are expressed on follicular dendritic cells and certain leukocytes including B lymphocytes and neutrophils. Recent results from biochemical studies and characterization of mice deficient in complement C3, C4 or the receptors CD21/CD35 has demonstrated an important link between innate immunity and regulation of the humoral immune response. The goal of this project is to examine the link between innate immunity and regulation of the repertoire of natural antibody and to define the mechanism of complement activation of mast cells. A murine model of acute septic peritonitis which is mast cell and classical pathway complement dependent will be used to examine the mechanisms of complement protection. The project includes three specific aims: (1) test the hypothesis that the repertoire of natural antibody is regulated by complement; (2) test the hypothesis that peritoneal mast cells are activated by complement receptors CD21/CD35 in the CLP model of acute septic peritonitis; (3) examine the importance of local synthesis of C3 in host defense against bacterial infection in the peritoneum. Understanding the regulation of the repertoire of natural antibody is important both for clarification of basic principles of the immune system and for development of novel therapeutic approaches in host defense against bacterial sepsis. Furthermore, elucidation of the mechanism of complement activation of mast cells is important for defining this important effector function of natural immunity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI036389-07
Application #
6510548
Study Section
Allergy and Immunology Study Section (ALY)
Program Officer
Voulgaropoulou, Frosso
Project Start
1995-09-15
Project End
2004-02-29
Budget Start
2002-03-01
Budget End
2003-02-28
Support Year
7
Fiscal Year
2002
Total Cost
$337,707
Indirect Cost
Name
Immune Disease Institute, Inc.
Department
Type
DUNS #
115524410
City
Boston
State
MA
Country
United States
Zip Code
02115
Carroll, Michael C (2004) The complement system in B cell regulation. Mol Immunol 41:141-6
Carroll, Michael C (2004) The complement system in regulation of adaptive immunity. Nat Immunol 5:981-6
Pozdnyakova, Olga; Guttormsen, Hilde-Kari; Lalani, Farah N et al. (2003) Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3- and complement receptor 2-deficient mice. J Immunol 170:84-90
Verschoor, Admar; Brockman, Mark A; Gadjeva, Mihaela et al. (2003) Myeloid C3 determines induction of humoral responses to peripheral herpes simplex virus infection. J Immunol 171:5363-71
Buono, Chiara; Come, Carolyn E; Witztum, Joseph L et al. (2002) Influence of C3 deficiency on atherosclerosis. Circulation 105:3025-31
Shapiro, Scott; Beenhouwer, David O; Feldmesser, Marta et al. (2002) Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect Immun 70:2598-604
Han, Y; Kozel, T R; Zhang, M X et al. (2001) Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J Immunol 167:1550-7
Yan, J; Vetvicka, V; Xia, Y et al. (1999) Beta-glucan, a ""specific"" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol 163:3045-52
Boes, M; Prodeus, A P; Schmidt, T et al. (1998) A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med 188:2381-6
Boes, M; Esau, C; Fischer, M B et al. (1998) Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. J Immunol 160:4776-87

Showing the most recent 10 out of 12 publications